| Effect | Increase |
| Trial Design | Double blind |
| Trial Length | n/a |
| Number of Subjects | 33 |
| Sex | Both Genders |
| Age Range | 45-64, 65+ |
| Body Types | Average |
Glutamine at 30g (average dose of 0.41+/-0.07g/kg bodyweight) in rectal cancer patients undergoing chemotherapy was investigated to see whether glutamine can confer gut protection during radiochemotherapy.
There were no effects of glutamine on diarrhea or inflammation that were different than placebo (maltodextrin) aside from an increase in IL-6 seen with glutamine supplementation. The increase in insulin seen was comparable, and although glucose trended to increase it did not reach significance.
